LC000307

_

==

2023 -- S 0098

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2023

AN ACT

RELATING TO FOOD AND DRUGS -- PRESCRIPTION DRUG COST PROTECTION

Introduced By: Senators DiPalma, Miller, Pearson, DiMario, Valverde, and Goodwin Date Introduced: February 01, 2023

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:


1	SECTION 1. Title 21 of the General Laws entitled "FOOD AND DRUGS" is he	reby
r	amonded by adding therets the following aborton	

2	amended by	adding	thereto the	following	chapter:
---	------------	--------	-------------	-----------	----------

3	CHAPTER 38
4	PRESCRIPTION DRUG COST PROTECTION
5	<u>21-38-1. Definitions.</u>
6	For the purposes of this chapter:
7	(1) "ERISA plan" means a plan qualified under the Employee Retirement Income Security
8	<u>Act of 1974.</u>
9	(2) "Health plan" means health insurance coverage or a plan providing coverage pursuant
10	to the provision of chapters 18.5, 18.6, 19 and 20 of title 27.
11	(3) "Participating ERISA plan" means an ERISA plan that has elected to participate in the
12	requirements and restrictions of this chapter as described in § 21-38-3.
13	(4) "Prescription drug" or "drug" has the same meaning as the term "drug" as defined in §
14	<u>5-19.1-2.</u>
15	(5) "Referenced drugs" means prescription drugs subjected to a referenced rate.
16	(6) "Referenced rate" means the maximum rate established by the health insurance
17	commissioner utilizing the wholesale acquisition cost and other pricing data pursuant to § 21-38-
18	<u>4.</u>

19 (7) "State entity" means any agency of state government that purchases prescription drugs

on behalf of the state for a person whose health care is paid for by the state, including any agent, 1 2 vendor, fiscal agent, contractor, or other party acting on behalf of the state. State entity does not include the medical assistance program established under 42 U.S.C. § 1396 et seq. 3 (8) "Wholesale acquisition cost" means, with respect to a drug or biological, the 4 5 manufacturer's list price for the drug or biological to wholesalers or direct purchasers in the United 6 States, not including prompt pay or other discounts, rebates or reductions in price, for the most 7 recent month for which the information is available, as reported in wholesale price guides or other 8 publications of drug or biological pricing data. 9 21-38-2. Payment in excess of referenced rate -- prohibited. 10 (a) It is a violation of this chapter for a state entity or health plan or participating ERISA 11 plan to purchase referenced drugs to be dispensed or delivered to a consumer in the state, whether 12 directly or through a distributor, for a cost higher than the referenced rate as determined in § 21-13 38-4. 14 (b) It is a violation of this chapter for a retail pharmacy licensed in this state to purchase 15 for sale or distribution referenced drugs for a cost that exceeds the referenced rate to a person whose 16 health care is provided by a state entity or health plan or participating ERISA plan. 17 21-38-3. ERISA plan opt-in. 18 An ERISA plan may elect to participate in the provisions of this chapter. Any ERISA plan 19 that desires its purchase of prescription drugs to be subject to the prohibition described in § 21-38-20 2 shall notify the health insurance commissioner in writing by February 1 of each year. 21 21-38-4. Referenced drugs determined. 22 (a) As of March 1 of each calendar year, the director of the state employee health insurance 23 plan shall transmit to the health insurance commissioner a list of the two hundred fifty (250) most costly prescription drugs based upon net price multiplied utilization. For each of these prescription 24 25 drugs, the director of the state employee health insurance plan shall also provide the total net spent 26 on each of those prescription drugs for the previous calendar year. 27 (b) Utilizing this information provided in subsection (a) of this section, as of May 1 of each 28 calendar year the health insurance commissioner shall create and publish a list of two hundred fifty 29 (250) referenced drugs that shall be subject to the referenced rate. 30 (c) The health insurance commissioner shall determine the referenced rate by comparing 31 the wholesale acquisition cost to the cost from the: 32 (1) Ontario ministry of health and long-term care and most recently published on the 33 Ontario drug benefit formulary; 34 (2) Régie de L'Assurance Maladie du Québec and most recently published on the Québec 1 public drug programs list of medications.



34 commissioner and to the attorney general one hundred eighty (180) days prior to withdrawal.

1 (c) The health insurance commissioner shall assess a penalty on any manufacturer or 2 distributor that it determines has withdrawn a referenced drug from distribution or sale in the state 3 in violation of § 21-38-7(a). With respect to each referenced drug for which the health insurance 4 commissioner has determined the manufacturer or distributor has withdrawn from the market, the 5 penalty shall be equal to five hundred thousand dollars (\$500,000) or the amount of annual savings 6 determined by the health insurance commissioner as described in § 21-38-4(e), whichever is 7 greater. 8 (d) It shall be a violation of this chapter for any manufacturer or distributor of a referenced 9 drug to refuse to negotiate in good faith with any payer or seller of prescription drugs a price that 10 is within the referenced rate as determined in §21-38-4. 11 (e) The health insurance commissioner shall assess a penalty on any manufacturer or 12 distributor that it determines has failed to negotiate in good faith in violation of subsection (d) of 13 this section. With respect to each referenced drug for which the health insurance commissioner has 14 determined the manufacturer or distributor has failed to negotiate in good faith, the penalty shall 15 be equal to five hundred thousand dollars (\$500,000) or the amount of annual savings determined 16 by the health insurance commissioner as described in § 21-38-4(e), whichever is greater. 17 21-38-8. Enforcement. 18 (a) Each violation of § 21-38-2 shall be subject to a fine of one thousand dollars (\$1,000). 19 Every individual transaction in violation of § 21-38-2 is determined to be a separate violation. 20 (b) The attorney general is authorized to enforce the provisions of this statute on behalf of any state entity or consumers of prescription drugs. The refusal of a manufacturer or distributor to 21 22 negotiate in good faith as described in § 21-38-7(d) shall be a valid affirmative defense in any 23 enforcement action for a violation of § 21-38-2. 24 21-38-9. Severability. 25 If any provision of this chapter or its application to any person or circumstances is held invalid, the invalidity shall not affect other provisions or applications of the chapter which can be 26 27 given effect without the invalid provision or application, and to this end the provisions of this 28 chapter are declared to be severable. 29 SECTION 2. This act shall take effect upon passage.

LC000307

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO FOOD AND DRUGS -- PRESCRIPTION DRUG COST PROTECTION

1 This act would prohibit the state, participating ERISA or any health plan from purchasing 2 referenced drugs for a cost higher than the referenced rate. The referenced rate will have two 3 hundred fifty (250) of the most costly prescription drugs based upon the net price multiplied by 4 utilization and the referenced rate shall be determined by comparing wholesale acquisition cost to the cost from various Canadian drug lists. Any manufacturer or distributor who fails to comply 5 with the purchase standards shall be subject to a penalty equal to five hundred thousand dollars 6 7 (\$500,000) or the amount of annual savings determined by the superintendent, whichever if greater. 8 Additionally, any manufacturer or distributor who fails to negotiate in good faith shall be subject 9 to a penalty of five hundred thousand dollars (\$500,000) or the amount of annual savings 10 determined by the health insurance commissioner, whichever is greater.

11

This act would take effect upon passage.

LC000307